Table 1 Relations between the level of LC3I/II or YBX1 expression and clinicopathologic characteristics in 100 NSCLC.
From: YBX1 mediates autophagy by targeting p110β and decreasing the sensitivity to cisplatin in NSCLC
Clinical factor | YBX1 | Expression | P value | LC3I/II | Expression | P value |
|---|---|---|---|---|---|---|
High (%) | Low (%) | High (%) | Low (%) | |||
Over all | 48 | 52 | 43 | 57 | ||
Gender | ||||||
Male | 23 (47.9) | 24 (46.2) | 0.156 | 18 (41.9) | 29 (50.9) | 0.422 |
Female | 25 (52.1) | 28 (53.8) | 25 (58.1) | 28 (49.1) | ||
Age | ||||||
<64 | 22 (45.8) | 27 (51.9) | 0.556 | 19 (44.2) | 30 (52.6) | 0.426 |
≥64 | 26 (54.2) | 25 (48.1) | 24 (55.8) | 27 (47.4) | ||
Smoke | ||||||
Yes | 29 (60.4) | 20 (38.5) | 0.045* | 21 (48.8) | 28 (49.1) | 1.000 |
No | 32 (61.5) | 19 (39.6) | 22 (51.2) | 29 (50.9) | ||
T | ||||||
T1 40(40) | 16 (33.3) | 24 (46.2) | 0.000* | 6 (14) | 34 (59) | 0.000* |
T2 37(37) | 17 (35.4) | 20 (38.4) | 23 (53.5) | 15 (24.6) | ||
T3 23(23) | 15 (31.3) | 8 (15.4) | 14 (32.6) | 9 (15.8) | ||
N | ||||||
N0 38(38) | 19 (39.6) | 19 (39.6) | 0.000* | 15 (34.9) | 35 (61.4) | 0.000* |
N1 23(23) | 15 (31.3) | 8 (15.4) | 10 (23.3) | 13 (22.8) | ||
N2 27(27) | 14 (29.1) | 13 (25) | 18 (41.9) | 9 (15.8) | ||
TNM | ||||||
I 46(46) | 18 (37.5) | 28 (53.8) | 0.000* | 12 (27.9) | 34 (59.6) | 0.000* |
II 20(20) | 9 (18.8) | 11 (21.2) | 9 (20.9) | 11 (19.3) | ||
III34(34) | 21 (43.7) | 13 (25) | 22 (51.2) | 12 (21.1) | ||
